These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 36566344)
1. Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study. Jiang C; Zhou H; Zhang W; Xia Y; Li B; Ni X; Wang G; Zhang W; Chen B; He Z; Zhang M; Chen R; Jin H; Deng L Dermatol Ther (Heidelb); 2023 Feb; 13(2):555-567. PubMed ID: 36566344 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis. Li Q; Qiao J; Jin H; Chen B; He Z; Wang G; Ni X; Wang M; Xia M; Li B; Chen R; Hu P Front Pharmacol; 2022; 13():966176. PubMed ID: 36052126 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. Jiang C; Du Y; Liu X; Wang J; Ge C; Xu J; Wang S; Li B; Zhu G; Zhang W; Qian Q; Ma C; Zhu X; Zhan Y; Yang Y Br J Dermatol; 2023 Dec; 190(1):28-36. PubMed ID: 37669307 [TBL] [Abstract][Full Text] [Related]
4. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013 [TBL] [Abstract][Full Text] [Related]
5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Spuls PI; Hooft L Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755 [TBL] [Abstract][Full Text] [Related]
8. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Papp KA; Weinberg MA; Morris A; Reich K Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. Svecova D; Lubell MW; Casset-Semanaz F; Mackenzie H; Grenningloh R; Krueger JG J Am Acad Dermatol; 2019 Jul; 81(1):196-203. PubMed ID: 30926369 [TBL] [Abstract][Full Text] [Related]
10. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192 [TBL] [Abstract][Full Text] [Related]
11. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. Nakagawa H; Niiro H; Ootaki K; J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K; Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070 [TBL] [Abstract][Full Text] [Related]
13. First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis. Gottlieb AB; Krueger JG; Sandberg Lundblad M; Göthberg M; Skolnick BE PLoS One; 2015; 10(8):e0134703. PubMed ID: 26252485 [TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. Anil Kumar MS; Papp K; Tainaka R; Valluri U; Wang X; Zhu T; Schwabe C Biopharm Drug Dispos; 2018 May; 39(5):245-255. PubMed ID: 29679478 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359 [TBL] [Abstract][Full Text] [Related]
16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J; Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225 [TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA; JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908 [TBL] [Abstract][Full Text] [Related]
18. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Puig L; Bakulev AL; Kokhan MM; Samtsov AV; Khairutdinov VR; Morozova MA; Zolkin NA; Kuryshev IV; Petrov AN; Artemeva AV; Zinkina-Orikhan AV Dermatol Ther (Heidelb); 2021 Aug; 11(4):1319-1332. PubMed ID: 34060012 [TBL] [Abstract][Full Text] [Related]
20. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]